Evidence map›Paper›PMID 21455236›Full record

ReviewNature reviews. Drug discovery2011

Targeting G-quadruplexes in gene promoters: a novel anticancer strategy?

Shankar Balasubramanian, Laurence H Hurley, Stephen Neidle

Open access · greenAbstract readReview
In one paragraph

Review in Nature reviews. Drug discovery, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 654 papers.

0numbers the graph read from it
0cells of the map it votes in
654citing papers in PubMed
45.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

654 citing papers in PubMed, 1,689 citations in OpenAlex.

  1. Article
  2. Light-Controlled Folding and Chiroptical Sensing of G-Quadruplex DNA.The journal of physical chemistry letters · 2026
    Article
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Review
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Review
  20. Article

594 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 3 institutions in 2 countries.

Shankar BalasubramanianDepartment of Chemistry, University of Cambridge, Cambridge CB21EW, UK. sb10031@cam.ac.uk
Laurence H Hurley
Stephen Neidle
Cancer Research UK · GBUniversity of Arizona · USUniversity of Cambridge · GB

Funding

SPORE in Gastrointestinal CancerP50CA095060 · NCI · UNIVERSITY OF ARIZONA · PI GERNER, EUGENE W · 2002 to 2012
$25.3M
Establishing a molecular system for drug targeting of transcriptional controlR01GM085585 · NIGMS · UNIVERSITY OF ARIZONA · PI HURLEY, LAURENCE H. · 2008 to 2011
$1.5M
G-quadruplexes formed in human oncogene promoters and their drug complexesR01CA122952 · NCI · UNIVERSITY OF ARIZONA · PI YANG, DANZHOU · 2007 to 2011
$875k
Biotechnology and Biological Sciences Research Council BB/E012752/1Cancer Research UK 11961Cancer Research UK A5709NCI NIH HHS CA122952NCI NIH HHS CA95060NCI NIH HHS P50 CA095060NCI NIH HHS R01 CA122952NIGMS NIH HHS GM085585NIGMS NIH HHS R01 GM085585
6 · The paper itself

Abstract

G-quadruplexes are four-stranded DNA structures that are over-represented in gene promoter regions and are viewed as emerging therapeutic targets in oncology, as transcriptional repression of oncogenes through stabilization of these structures could be a novel anticancer strategy. Many gene promoter G-quadruplexes have physicochemical properties and structural characteristics that might make them druggable, and their structural diversity suggests that a high degree of selectivity might be possible. Here, we describe the evidence for G-quadruplexes in gene promoters and discuss their potential as therapeutic targets, as well as progress in the development of strategies to harness this potential through intervention with small-molecule ligands.

Indexed as

Drug Delivery SystemsG-QuadruplexesAnimalsAntineoplastic AgentsDrug DesignHumansNeoplasmsPromoter Regions, GeneticAntineoplastic Agents

Identifiers

PMID21455236
PMCPMC3119469
OpenAlexW2059306569

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.